Research programme: renin inhibitors 800 series - Speedel/Locus

Drug Profile

Research programme: renin inhibitors 800 series - Speedel/Locus

Alternative Names: SPP 800

Latest Information Update: 11 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Locus Pharmaceuticals; Speedel Experimenta
  • Developer Novartis
  • Class
  • Mechanism of Action Renin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypertension

Most Recent Events

  • 28 Jan 2009 Discontinued - Preclinical for Hypertension in Switzerland (unspecified route)
  • 09 Jul 2008 Speedel has been acquired by Novartis
  • 05 Apr 2006 This programme is still in active development - (BIO-Europe-2005)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top